D. Boral Capital analyst Jason Kolbert says investors should “stay the course” on Carisma Therapeutics (CARM) amid the rating downgrades following the company’s announcement to discontinue development of CT-0525 for HER2+ cancers. The firm, which has a Buy rating on the name with a $12 price target says it continues to assign “substantial value” to Carisma’s CAR-M platform. The platform’s “transformative potential” supports a Buy rating and Moderna’s (MRNA) confidence in Carisma “further reinforces our conviction,” contends D. Boral.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics downgraded to Neutral from Outperform at Baird
- Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Carisma Therapeutics downgraded to Neutral from Buy at BTIG
- Carisma Therapeutics price target lowered to $12 from $24 at D. Boral Capital
- Carisma Therapeutics announces restructuring, 34% workforce reduction